Unusual early-stage pancreatic sarcomatoid carcinoma  被引量:3

Unusual early-stage pancreatic sarcomatoid carcinoma

在线阅读下载全文

作  者:Chuan-Li Ren Ping Jin Chong-Xu Han Qin Xiao Dao-Rong Wang Lin Shi Da-Xin Wang Hui Chen 

机构地区:[1]Laboratory Medicine and Pathology Department,Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University [2]Pathology Department,Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University [3]Abdominal Surgery Department,Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University [4]Transonogram Department,Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University [5]Laboratory Medicine Centre Department,Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University [6]Geratology Department,Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University

出  处:《World Journal of Gastroenterology》2013年第43期7820-7824,共5页世界胃肠病学杂志(英文版)

基  金:Supported by China Postdoctoral Science Foundation,No.2013M541699;Social Development of Jiangsu Province,No.BE2012705;the Foundation of Northern Jiangsu People’s Hospital,No.Yzucms201213

摘  要:Sarcomatoid carcinoma of the pancreas(SCP)is a very rare pathological type of carcinoma that usually has a poor prognosis.Its pathogenesis has not been elucidated.We herein report a case of an early-stage SCP involving successful treatment and a good prognosis.The patient was a 48-year-old Chinese man with a5-mo history of vague abdominal pain.Ultrasonography revealed a 93 mm×94 mm×75 mm mass of mixed echogenicity in the tail of the pancreas.Laboratory test results were within the normal range,with the exception of an obviously increased pretreatment neuron-specific enolase level.The plasma transforming growth factor(TGF)β1 and interleukin-11 levels were obviously increased according to enzyme-linked immunosorbent assay.Microscopically,the excised tumor tissue comprised cancer cells and mesenchymal cells.Immunohistochemical analysis was positive forα-1-antichymotrypsin,pan-cytokeratin,cytokeratin 19,cytokeratin 8/18,and vimentin and negative for CD68and lysozyme.The pathogenetic mechanism of this case shows that TGFβ1 may regulate the epithelial-tomesenchymal transition in SCP.With early eradication of the tumor and systemic therapy,this patient has been alive for more than 3 years without tumor recurrence or distant metastasis.This case is also the first to show that TGFβ1 may regulate the epithelial-tomesenchymal transition in early-stage SCP.Sarcomatoid carcinoma of the pancreas (SCP) is a very rare pathological type of carcinoma that usually has a poor prognosis. Its pathogenesis has not been elucidated. We herein report a case of an early-stage SCP involving successful treatment and a good prognosis. The patient was a 48-year-old Chinese man with a 5-mo history of vague abdominal pain. Ultrasonography revealed a 93 mm × 94 mm × 75 mm mass of mixed echogenicity in the tail of the pancreas. Laboratory test results were within the normal range, with the exception of an obviously increased pretreatment neuron-specific enolase level. The plasma transforming growth factor (TGF)β1 and interleukin-11 levels were obviously increased according to enzyme-linked immunosorbent assay. Microscopically, the excised tumor tissue comprised cancer cells and mesenchymal cells. Immunohistochemical analysis was positive for α-1-antichymotrypsin, pan-cytokeratin, cytokeratin 19, cytokeratin 8/18, and vimentin and negative for CD68 and lysozyme. The pathogenetic mechanism of this case shows that TGFβ1 may regulate the epithelial-to-mesenchymal transition in SCP. With early eradication of the tumor and systemic therapy, this patient has been alive for more than 3 years without tumor recurrence or distant metastasis. This case is also the first to show that TGFβ1 may regulate the epithelial-to-mesenchymal transition in early-stage SCP.

关 键 词:SARCOMATOID carcinoma of the PANCREAS Transforming growth factorβ1 Epithelial-to MESENCHYMAL transition INTERLEUKIN-11 VIMENTIN 

分 类 号:R735.9[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象